Bortezomib for Refractory Immune-Mediated Thrombocytopenia Purpura

Joan D. Beckman; Marian A. Rollins-Raval; Jay S. Raval; Yara A. Park; Marshall Mazepa; Alice Ma

doi:10.1097/MJT.0000000000000517

Bortezomib for Refractory Immune-Mediated Thrombocytopenia Purpura

Joan D. Beckman, Marian A. Rollins-Raval, Jay S. Raval, Yara A. Park, Marshall Mazepa, Alice Ma

Medicine - Hematology, Oncology, Transplant

Research output: Contribution to journal › Article › peer-review

3 Scopus citations

Abstract

The treatment of refractory immune-mediated thrombocytopenia purpura (ITP) can be challenging. This case report describes treatment of refractory ITP with bortezomib, a proteasome inhibitor. This strategy has been successful in relapsing thrombotic thrombocytopenic purpura but is a novel therapeutic approach for ITP. Further research use of proteasome inhibition in refractory ITP may be warranted.

Original language	English (US)
Pages (from-to)	e270-e272
Journal	American journal of therapeutics
Volume	25
Issue number	2
DOIs	https://doi.org/10.1097/MJT.0000000000000517
State	Published - Mar 1 2018

Access

10.1097/MJT.0000000000000517

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5753577

Fingerprint Dive into the research topics of 'Bortezomib for Refractory Immune-Mediated Thrombocytopenia Purpura'. Together they form a unique fingerprint.

Cite this

@article{7898ecb17c774c79b942cea3ad56a798,

title = "Bortezomib for Refractory Immune-Mediated Thrombocytopenia Purpura",

abstract = "The treatment of refractory immune-mediated thrombocytopenia purpura (ITP) can be challenging. This case report describes treatment of refractory ITP with bortezomib, a proteasome inhibitor. This strategy has been successful in relapsing thrombotic thrombocytopenic purpura but is a novel therapeutic approach for ITP. Further research use of proteasome inhibition in refractory ITP may be warranted.",

author = "Beckman, {Joan D.} and Rollins-Raval, {Marian A.} and Raval, {Jay S.} and Park, {Yara A.} and Marshall Mazepa and Alice Ma",

note = "Copyright: This record is sourced from MEDLINE{\textregistered}/PubMed{\textregistered}, a database of the U.S. National Library of Medicine",

year = "2018",

month = mar,

day = "1",

doi = "10.1097/MJT.0000000000000517",

language = "English (US)",

volume = "25",

pages = "e270--e272",

journal = "American Journal of Therapeutics",

issn = "1075-2765",

publisher = "Lippincott Williams and Wilkins",

number = "2",

}

TY - JOUR

T1 - Bortezomib for Refractory Immune-Mediated Thrombocytopenia Purpura

AU - Beckman, Joan D.

AU - Rollins-Raval, Marian A.

AU - Raval, Jay S.

AU - Park, Yara A.

AU - Mazepa, Marshall

AU - Ma, Alice

N1 - Copyright: This record is sourced from MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

PY - 2018/3/1

Y1 - 2018/3/1

N2 - The treatment of refractory immune-mediated thrombocytopenia purpura (ITP) can be challenging. This case report describes treatment of refractory ITP with bortezomib, a proteasome inhibitor. This strategy has been successful in relapsing thrombotic thrombocytopenic purpura but is a novel therapeutic approach for ITP. Further research use of proteasome inhibition in refractory ITP may be warranted.

AB - The treatment of refractory immune-mediated thrombocytopenia purpura (ITP) can be challenging. This case report describes treatment of refractory ITP with bortezomib, a proteasome inhibitor. This strategy has been successful in relapsing thrombotic thrombocytopenic purpura but is a novel therapeutic approach for ITP. Further research use of proteasome inhibition in refractory ITP may be warranted.

UR - http://www.scopus.com/inward/record.url?scp=85053903627&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85053903627&partnerID=8YFLogxK

U2 - 10.1097/MJT.0000000000000517

DO - 10.1097/MJT.0000000000000517

M3 - Article

C2 - 29293474

AN - SCOPUS:85053903627

VL - 25

SP - e270-e272

JO - American Journal of Therapeutics

JF - American Journal of Therapeutics

SN - 1075-2765

IS - 2

ER -

Bortezomib for Refractory Immune-Mediated Thrombocytopenia Purpura

Abstract

Access

Other files and links

Cite this